CareDx, Inc (CDNA)
Pre-Market:
| Previous Close | 17.61 |
| Open | 17.08 |
| Bid | 16.00 x 800 |
| Ask | 17.90 x 1200 |
| Day's Range | 16.40 - 17.32 |
| 52 Week Range | 10.50 - 46.88 |
| Volume | |
| Avg. Volume | 1,043,224 |
| Market Cap | 885.507M |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.00 |
- Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Let's not try to jinx things by calling attention to this, but Cathie Wood's on a roll this year. The largest of the exchange-traded funds she runs at Ark Investment Management is up nearly 23% this month. Wood added to her existing stakes in Pinterest (NYSE: PINS), CareDx (NASDAQ: CDNA), and Teladoc Health (NYSE: TDOC) yesterday.
- Simply Wall St.
CareDx (NASDAQ:CDNA) delivers shareholders splendid 20% CAGR over 5 years, surging 9.8% in the last week alone
CareDx, Inc ( NASDAQ:CDNA ) shareholders might be concerned after seeing the share price drop 24% in the last quarter...
- Business Wire
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
BRISBANE, Calif., January 26, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito
